ClinicalTrials.gg
Not yet recruitingNCT04728412BroncHoFlowUpdated Feb 13, 2024

High Flow Oxygen Therapy in Patients Undergoing Bronchoscopy Under Sedation

An interventional study of High Flow Oxygen Therapy (HFOT) in Respiratory Failure and Hypercapnic Acidosis, sponsored by Cardarelli Hospital. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Cardarelli Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 112 studies in Respiratory Insufficiency with a site in Italy — 27 open to participants now, 28 under way, 2 of them phase 3. Respiratory Insufficiency · Italy.

Planned enrollment
26th of 65
100 · median 55
Started
2024
with 11 others
No phase
51 of 112
12 open now
Primary completion
2025-09
later than 7 of 27 live
Registered
73rd of 112
by date

Among the 112 studies in Respiratory Insufficiency with a site in Italy, this one is the 26th largest by planned enrollment of the 65 interventional ones that give a count, is one of 12 that started in 2024, is one of 51 with no phase, reaches primary completion later than 7 of the 27 other live ones, and was the 73rd registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

27 of the 112 studies in Respiratory Insufficiency with a site in Italy are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Respiratory Insufficiency with a site in Italy, or all of them as a file.
02

Study summary

A reduction of peripheral oxygen saturation (SpO2) commonly occurs during bronchoscopy and may be associated with both respiratory and cardiac adverse events. The type of breathing assistance that should be delivered to patients, in order to treat and/or to prevent acute respiratory failure, during or after bronchoscopy, is not universally standardized; studies comparing the impact of different respiratory supports on patient's outcome and on hospital resource use are very few. the risk of respiratory failure rises according to the type of procedure (i.e., increased risk with broncho-alveolar lavage and trans-bronchial lung biopsy) and to the use of sedative drugs. Conventional oxygen therapy with nasal cannula, continuous positive airway pressure and non-invasive ventilation are commonly applied during endoscopic procedures. High flow oxygen therapy (HFOT) is a relatively novel device, still under-used in the context of interventional pulmonology, providing an humidified air-oxygen blend up to 60 L/min. HFOT has been reported to be effective for the treatment of both hypoxemic and hypercapnic respiratory failure. The investigators hypothesize that HFOT could be feasible and safe in patients undergoing bronchoscopy under moderate sedation, affected by or at risk of hypoxemic and/or hypercapnic respiratory failure.

03

Conditions studied

  • Respiratory Failure
  • Hypercapnic Acidosis

Keywords

  • bronchoscopy
  • sedation
  • high flow oxygen therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pH ≥7.30 e PaCO2 >45 mmHg and/or
  • PaO2/FiO2 \<300 mmHg o SpO2 \<90 percent on room air
  • Patient at risk of respiratory failure ( III-IV GOLD stage; OSAS; restrictive lung and chest wall diseases; cardiac failure)

Exclusion criteria

Exclusion Criteria:

  • Need of laryngeal mask and/or
  • Patients on NIV for >16 hrs/day and/or
  • pH \<7.30 and/or
  • Tracheostomy and/or
  • Recent (\<3 months) facial trauma and/or
  • Hemodynamic instability and/or
  • High risk of aspiration and/or
  • Lacerated trachea
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    patients undergoing bronchoscopy under sedation with or at risk of respiratory failure

    Device: High Flow Oxygen Therapy (HFOT)

Interventions

  • DeviceHigh Flow Oxygen Therapy (HFOT)

    HFOT administration in patients undergoing bronchoscopy under moderate sedation, affected by or at risk of hypoxemic and/or hypercapnic respiratory failure.

06

What researchers measure

Primary outcomes

  1. Number of desaturation, defined as SpO2< 90 percent percent for >1 min, <5.

    Time frame: one year

  2. Percent of variation of pH, comparing ABG performed before bronchoscopy with that performed before partecipant's transferral to recovery room.

    Time frame: one year

  3. Percent of variation of PaCO2 variation, comparing ABG performed before bronchoscopy with that performed before partecipant's transferral to recovery room.

    Time frame: one year

  4. Rate of interruption of bronchoscopy because of number of desaturation, defined as SpO2< 90 percent for >1 min, >5.

    Time frame: one year

  5. Number of partecipants requiring an escalation of respiratory support.

    Time frame: one year

  6. Rate of new appearance of hemodynamic instability.

    Time frame: one year

Secondary outcomes

  1. value of Charlson Comobidity Index associated with HFOT failure.

    Time frame: one year

  2. value of Body Mass Index associated with HFOT failure.

    Time frame: one year

  3. value of Borg dyspnea scale associated with HFOT failure.

    Time frame: one year

  4. Number of desaturations, defined as SpO2< 90 percent for >1 min.

    Time frame: one year

  5. Lowest oxygen saturation under HFOT.

    Time frame: one year

  6. Rate of change of HFOT parameters because of desaturation without respiratory acidosis.

    Time frame: one year

  7. Rate of change of HFOT parameters because of desaturation with respiratory acidosis

    Time frame: one year

07

Study locations

1 site
  • Giuseppe Failla, MD
    Naples, 80131, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Sep 2025, 12 months later.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2020
First posted
Jan 28, 2021
StartEst.
Sep 1, 2024
Primary completionEst.
Sep 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04728412
Lead sponsor
Cardarelli Hospital
Responsible party
Giuseppe Failla (Chief of Interventional Pulmonology Unit, Cardarelli Hospital) — Principal investigator
First posted
Jan 28, 2021
Start date
Sep 1, 2024 (estimated)
Primary completion
Sep 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Feb 13, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion